Trial Profile
A Multicenter Study to Collect Samples for Future Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease (CD) or Ulcerative Colitis (UC) Who Developed Hepatosplenic T-Cell Lymphoma (HSTCL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacodynamics
- Sponsors AbbVie
- 20 Nov 2019 Planned End Date changed from 13 Mar 2022 to 30 Sep 2019.
- 20 Nov 2019 Planned primary completion date changed from 13 Mar 2022 to 30 Sep 2019.
- 20 Nov 2019 Status changed from recruiting to withdrawn prior to enrolment.